In aggregate, these findings indicate that blood NfL could facilitate the identification of presymptomatic mutation carriers approaching phenoconversion; nevertheless, it is likely that the addition of traits, such as age and mutation status, would better approximate when clinically manifest ALS will occur. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.